Skip to main content
SpringerLink
Log in

Axitinib

In Advanced, Treatment-Experienced Renal Cell Carcinoma

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Axitinib is a new inhibitor of vascular endothelial growth factor (VEGF) receptors 1–3, with greater inhibition potency than existing VEGF receptor inhibitors sunitinib, sorafenib and pazopanib.

In a pivotal phase III trial in patients with advanced renal cell carcinoma that had progressed despite first-line therapy, axitinib 5 mg twice daily significantly prolonged median progression-free survival (primary endpoint) compared with sorafenib 400 mg twice daily. A significant between-group difference favouring axitinib over sorafenib in terms of progression-free survival was maintained in the subgroups of patients who had previously received cytokine or sunitinib therapy. However, median overall survival was not significantly different between the treatment groups.

Significantly more axitinib than sorafenib recipients achieved an objective response, and axitinib therapy significantly prolonged time to deterioration (a composite endpoint of death, disease progression and symptom worsening) relative to sorafenib therapy.

While its tolerability profile was generally consistent with that of other VEGF receptor inhibitors, axitinib was associated with a numerically lower incidence of palmar-plantar erythrodysaesthesia, cutaneous toxicity and anaemia than sorafenib in the phase III trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011 Oct; 60(4): 615–21

    Article  PubMed  Google Scholar 

  2. Cho E, Adami HO, Lindblad P. Epidemiology of renal cell cancer. Hematol Oncol Clin North Am 2011 Aug; 25(4): 651–65

    Article  PubMed  Google Scholar 

  3. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010 Sep; 58(3): 398–406

    Article  PubMed  Google Scholar 

  4. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010 Feb–Apr; 13(1–2): 16–28

    Article  PubMed  CAS  Google Scholar 

  5. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010 Aug; 36(5): 416–24

    Article  PubMed  CAS  Google Scholar 

  6. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 Feb 10; 23(5): 1011–27

    Article  PubMed  CAS  Google Scholar 

  7. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004 Feb; 93(3): 297–302

    Article  PubMed  CAS  Google Scholar 

  8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer (version 2.2012) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf [Accessed 2012 Nov 8]

  9. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011; 11(2): 113–26

    Article  PubMed  Google Scholar 

  10. Pfizer Inc. Inlyta® (axitinib) oral tablets: US prescribing information [online]. Available from URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=759 [Accessed 2012 Nov 8]

  11. European Medicines Agency. Inlyta® film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002406/WC500132188.pdf [Accessed 2012 Nov 8]

  12. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008 Nov 15; 14(22): 7272–83

    Article  PubMed  CAS  Google Scholar 

  13. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, and oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005 Aug 20; 23(24): 5464–73

    Article  PubMed  CAS  Google Scholar 

  14. Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs. Epub 2010 Feb 12

    Google Scholar 

  15. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8(11): 975–84

    Article  PubMed  Google Scholar 

  16. Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 2011; 47(17): 2592–602

    Article  PubMed  CAS  Google Scholar 

  17. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27(27): 4462–8

    Article  PubMed  CAS  Google Scholar 

  18. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial [published erratum appears in Lancet 2012 Nov 24; 380 (9856): 1818]. Lancet 2011 Dec 3; 378(9807): 1931–9

    Article  PubMed  CAS  Google Scholar 

  19. Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17(11): 3841–9

    Article  PubMed  CAS  Google Scholar 

  20. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 2009 May; 20(5): 966–7

    Article  PubMed  CAS  Google Scholar 

  21. Rini BI, Grünwald V, Fishman MN, et al. Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study [abstract no. 4503]. J Clin Oncol 2012; 30 Suppl.

    Google Scholar 

  22. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20(1–2): 79–86

    Article  PubMed  CAS  Google Scholar 

  23. Pithavala YK, Chen Y, Toh M, et al. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemother Pharmacol 2012 Jul; 70(1): 103–12

    Article  PubMed  CAS  Google Scholar 

  24. Tortorici MA, Toh M, Rahavendran SV, et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs 2011 Dec; 29(6): 1370–80

    Article  PubMed  CAS  Google Scholar 

  25. Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010 Feb; 65(3): 563–70

    Article  PubMed  CAS  Google Scholar 

  26. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005 Aug 20; 23(24): 5474–83

    Article  PubMed  CAS  Google Scholar 

  27. Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011 Nov; 108(10): 1556–63

    Article  PubMed  CAS  Google Scholar 

  28. Michaelson MD, Rini BI, Escudier BJ, et al. Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: updated results among cytokine-treated patients [abstract no. 4546]. J Clin Oncol 2012; 30 Suppl.

    Google Scholar 

  29. McKee A. FDA Oncologic Drugs Advisory Committee review [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM 283656.pdf [Accessed 2012 Nov 8]

  30. Trask PC, Bushmakin AG, Cappelleri JC, et al. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol 2008; 47(5): 843–51

    Article  PubMed  CAS  Google Scholar 

  31. Inlyta® tablets. Japanese prescribing information. Tokyo: Pfizer, 2012

  32. Pfizer. Axitinib (AG-013736) for the treatment of metastatic renal cell cancer [ClinicalTrials.gov identifier NCT00920816]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Nov 8]

Download references

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Lily P. H. Yang & Kate McKeage

Authors
  1. Lily P. H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lily P. H. Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, L.P.H., McKeage, K. Axitinib. Drugs 72, 2375–2384 (2012). https://doi.org/10.2165/11209230-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11209230-000000000-00000

Keywords

Search

Navigation